ExpreS2ion Biotechnologies: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 9 November 2023
Helsingborg, Sweden, 9 November 2023 - The extraordinary general meeting ("EGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today, 9 November 2023, in Helsingborg, Sweden.
Resolution regarding incentive program 2023/2026 for senior executives and employees through issuance of warrants and approval of transfer of the warrants
The EGM resolved in accordance with the board of directors’ proposal that the Company will implement an incentive program through issuance of warrants to senior executives, key persons and other employees within the company group and to ExpreS2ion Biotechnologies ApS (the "Subsidiary") with subsequent transfer to senior executives, key persons and other employees within the company group ("Incentive program 2023/2026").
As a result of Incentive program 2023/2026, the Company will issue a maximum of 2,000,000 warrants, which may result in a maximum increase in the Company's share capital of SEK 222,222.222625 which corresponds to a dilution of approximately 4 percent of the total number of shares and votes in the Company.
The warrants shall be subscribed for by senior executives, key persons and other employees in the company group and the Subsidiary, with the right and obligation to, at one or several occasions, transfer the warrants to senior executives, key persons and other employees who are or will become employed by the company group, at a price equal to the fair market value of the warrant or at no consideration (subject to being tax neutral for the company group) and otherwise on the same terms as in the issuance. The Subsidiary has the right to subscribe for warrants without consideration and the senior executives, key persons and other employees in the company group have the right to subscribe for the warrants at a price equal to the warrant's market value or at no consideration (subject to being tax neutral for the company group).
Each warrant entitles to subscription of one (1) new share in the Company during the period from and including 15 November 2026 up to and including 15 December 2026 or an earlier or later date in accordance with the terms and conditions for the warrants. The subscription price shall be determined to an amount equal to 130 percent of the volume weighted average price at Nasdaq First North Growth Market during ten trading days up to and including the day of the EGM.
For further details regarding the resolution set out above, please see the complete proposal in the notice to the EGM, www.expreS2ionbio.com.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB